The Wall Street Journal57d agobearish
Biogen Cuts FY Adjusted View as Profit DeclinesBiogen’s second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
Zacks62d agobearish
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Investing.com72d agobearish
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradoxInvesting.com -- Biogen Inc. (NASDAQ:BIIB) shares fell nearly 9% following the Phase 2 CELIA readout of its highly anticipated Alzheimer’s therapy, diranersen. While the drug achieved a major scientific milestone by robustly clearing tau pathology, an unexpected inverse dose response—where the lowest dose performed the best—left Wall Street analysts confused and triggered a sell-off. Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cogniti